Literature DB >> 19744734

Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study.

Miho Yasuda1, Yutaka Kiyohara, Yasuaki Hata, Satoshi Arakawa, Koji Yonemoto, Yasufumi Doi, Mitsuo Iida, Tatsuro Ishibashi.   

Abstract

PURPOSE: To estimate the 9-year incidence and risk factors for age-related macular degeneration (AMD) in a general Japanese population.
DESIGN: Population-based, cohort study. PARTICIPANTS: In 1998, a total of 1775 Hisayama residents aged >or=40 years underwent a baseline eye examination. Of those, 1401 subjects (78.9%) took part in the follow-up eye examination in 2007 and were enrolled in the present study.
METHODS: At both time points, the characteristics of AMD were determined by grading color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System. MAIN OUTCOME MEASURES: Incident early and late AMD.
RESULTS: The age-standardized, 9-year cumulative incidence of early AMD was 10.0%, and that of late AMD was 1.4%. Men were found to have a significantly higher incidence of late AMD than women (age-adjusted odds ratio [OR], 2.97; 95% confidence interval [CI], 1.25-7.09). The incidence of both early and late AMD increased significantly with age. Multiple logistic regression analysis showed that older age (per 1 year; OR, 1.10; 95% CI, 1.05-1.16), smoking habits (OR, 3.98; 95% CI, 1.07-14.7), and higher circulating white blood cell (WBC) count (per 1000 cells/mm(3)) (OR, 1.38; 95% CI, 1.07-1.79) were significantly associated with the development of late AMD.
CONCLUSIONS: Our findings suggest that the 9-year incidences of late AMD are lower among the Japanese than among white people in Western countries, and it is higher than among black people. Smoking habits and higher circulating WBC count are significant risk factors for the development of late AMD in the Japanese.

Entities:  

Mesh:

Year:  2009        PMID: 19744734     DOI: 10.1016/j.ophtha.2009.04.017

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  47 in total

1.  Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups.

Authors:  Joshua D Stein; Brian L Vanderbeek; Nidhi Talwar; Bin Nan; David C Musch; David N Zacks
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-29       Impact factor: 4.799

2.  Genome-wide association study identifies two susceptibility loci for exudative age-related macular degeneration in the Japanese population.

Authors:  Satoshi Arakawa; Atsushi Takahashi; Kyota Ashikawa; Naoya Hosono; Tomomi Aoi; Miho Yasuda; Yuji Oshima; Shigeo Yoshida; Hiroshi Enaida; Takashi Tsuchihashi; Keisuke Mori; Shigeru Honda; Akira Negi; Akira Arakawa; Kazuaki Kadonosono; Yutaka Kiyohara; Naoyuki Kamatani; Yusuke Nakamura; Tatsuro Ishibashi; Michiaki Kubo
Journal:  Nat Genet       Date:  2011-09-11       Impact factor: 38.330

3.  Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report.

Authors:  Akitaka Tsujikawa; Yumiko Akagi-Kurashige; Mitsuko Yuzawa; Tatsuro Ishibashi; Hideo Nakanishi; Eiji Nakatani; Satoshi Teramukai; Masanori Fukushima; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2017-12-21       Impact factor: 2.447

4.  Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.

Authors:  Ikuko Kachi; Tsutomu Yasukawa; Aki Kato; Noriaki Takase; Hiroshi Morita; Ayae Kubota; Yoshio Hirano; Akiyoshi Uemura; Yuichiro Ogura
Journal:  Jpn J Ophthalmol       Date:  2016-02-26       Impact factor: 2.447

5.  Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept.

Authors:  Chikako Hara; Taku Wakabayashi; Yoko Fukushima; Kaori Sayanagi; Ryo Kawasaki; Shigeru Sato; Hirokazu Sakaguchi; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-09-03       Impact factor: 3.117

6.  Incidence of and Risk Factors Associated With Age-Related Macular Degeneration: Four-Year Follow-up From the ALIENOR Study.

Authors:  Valentine Saunier; Bénédicte M J Merle; Marie-Noëlle Delyfer; Audrey Cougnard-Grégoire; Marie-Bénédicte Rougier; Philippe Amouyel; Jean-Charles Lambert; Jean-François Dartigues; Jean-François Korobelnik; Cécile Delcourt
Journal:  JAMA Ophthalmol       Date:  2018-05-01       Impact factor: 7.389

7.  Reconsideration of the most appropriate criterion in the lowest classification of vision disability in Japan.

Authors:  Tomomi Nishida; Noburo Ando; Kazushige Sado; Satoshi Nakadomari
Journal:  Jpn J Ophthalmol       Date:  2011-08-24       Impact factor: 2.447

8.  Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.

Authors:  Fumi Gomi; Hideyuki Migita; Toshiaki Sakaguchi; Hiromi Okada; Tamotsu Sugawara; Yusuke Hikichi
Journal:  Jpn J Ophthalmol       Date:  2019-10-31       Impact factor: 2.447

9.  Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network.

Authors:  Brian L Vanderbeek; David N Zacks; Nidhi Talwar; Bin Nan; David C Musch; Joshua D Stein
Journal:  Am J Ophthalmol       Date:  2011-06-22       Impact factor: 5.258

10.  Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.

Authors:  Izumi Yoshida; Tomoaki Shiba; Hikari Taniguchi; Mao Takahashi; Takeyoshi Murano; Nobuyuki Hiruta; Yuichi Hori; Hdieaki Bujo; Takatoshi Maeno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.